Lysophosphatidylcholine 18:2-d₉  (Synonyms: 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC-d₉)

Lysophosphatidylcholine 18:2-d₉ is deuterium labeled Lysophosphatidylcholine 18:2. Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

528.71

C₂₆H₄₁D₉NO₇P

2162167-92-0

22252-07-9

CCCCC/C=C\C/C=C\CCCCCCCC(OC[C@@H](O)COP(OCC[N+](C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])([O-])=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gonzalez-Freire M, et al. Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci. 2019;74(1):62-67.  [Content Brief]

  [2]. Chen YX, et al. UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance. J Pharm Biomed Anal. 2016;121:141-150.  [Content Brief]

  [3]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.  [Content Brief]